{
"id":"mk19_b_en_s6",
"subspecialtyId":"en",
"title":"Transgender Hormone Therapy Management",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s6",
"title":{
"__html":"Transgender Hormone Therapy Management"
},
"titleNode":{
"type":"section-title",
"hlId":"c36c33",
"children":[
"Transgender Hormone Therapy Management"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s6_0",
"children":[
{
"type":"p",
"hlId":"63ba2f",
"children":[
"Transgender medicine involves the care of persons whose gender identity differs from their gender assignment at birth. A male transgender person was assigned female gender at birth but identifies as male. A female transgender person was assigned male gender at birth but identifies as female. Gender dysphoria is the distress experienced if gender identity and designated gender are incongruent. Gender-affirming treatment is hormonal or surgical therapy used to adapt the patient's body to their experienced gender. Before initiating treatment, discussion is needed about risks, medical conditions that can be exacerbated by therapy, the time course of physical changes, and fertility preservation. Treatment must be individualized to the patient's goals."
]
},
{
"type":"p",
"hlId":"490b94",
"children":[
"Transgender persons may avoid seeking health care because of discriminatory or disrespectful interactions in previous health care encounters. Providing a respectful environment, including use of appropriate pronouns, is critical to ensure that transgender persons establish and continue primary and gender-affirming care. Accurate collection of gender identity information is important. To avoid invisibility of transgender status, many organizations use a “two-step” method to collect these data: (1) gender identity, and (2) sex listed on the original birth certificate. Before physical examination, a patient history is necessary to understand a person's anatomic changes associated with gender-affirming treatment because secondary sex characteristics present on a wide spectrum of development in transgender patients."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s6_1",
"title":{
"__html":"Gender-Affirming Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"cf9d6f",
"children":[
"Gender-Affirming Treatment"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s6_1_1",
"title":{
"__html":"Hormonal Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"fd7b87",
"children":[
"Hormonal Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"602c66",
"children":[
"Gender-affirming hormone therapy is the most common medical intervention sought by transgender persons and does not require subspecialty care. Criteria for gender-affirming hormone therapy are persistent, well-documented gender dysphoria, capacity to make a fully informed decision, age of majority in a given country, and, if present, control of significant medical or psychologic conditions."
]
},
{
"type":"section",
"id":"mk19_b_en_s6_1_1_1",
"title":{
"__html":"Feminizing Hormones"
},
"titleNode":{
"type":"section-title",
"hlId":"c383ff",
"children":[
"Feminizing Hormones"
]
},
"children":[
{
"type":"p",
"hlId":"952a74",
"children":[
"Feminizing hormone therapy is typically estradiol in combination with an androgen blocker ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t43",
"wrapId":"1",
"children":[
"Table 43"
]
}
]
},
")"
]
},
". Estrogen therapy increases the risk of deep venous thrombosis, particularly in patients who use tobacco or are older than 35 years. Tobacco cessation should be encouraged before initiation of estrogen therapy in female transgender patients to reduce this risk. Other potential risks of estrogen therapy are gallstones, elevated liver enzymes, weight gain, and hypertriglyceridemia. With additional risk factors, estrogen therapy could raise the risk of myocardial infarction, stroke, hypertension, diabetes mellitus type 2, and hyperprolactinemia. Effects of therapy include body fat redistribution, breast growth, softened skin, decreased muscle mass, reduced libido and spontaneous erections, decreased testicular volume and sperm production, and slowed growth of body hair. The expected onset of these changes varies from 1 to 6 months, with maximum effect by 2 to 3 years. Contraindications to estrogen therapy include history of venous thromboembolism, estrogen-sensitive neoplasm, and end-stage liver disease. Antiandrogen therapy, such as spironolactone, diminishes secondary male sex characteristics and minimizes the estrogen dose needed, thus reducing risks associated with high-dose exogenous estrogen therapy."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_t43"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s6_1_1_2",
"title":{
"__html":"Masculinizing Hormones"
},
"titleNode":{
"type":"section-title",
"hlId":"40fc7f",
"children":[
"Masculinizing Hormones"
]
},
"children":[
{
"type":"p",
"hlId":"6ca2ed",
"children":[
"Masculinizing hormone therapy is achieved by testosterone administration (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t43",
"wrapId":"2",
"children":[
"Table 43"
]
}
]
},
")"
]
},
". Effects of therapy include acne, increased body hair, scalp hair loss, increased muscle mass, body fat redistribution, cessation of menses, clitoral enlargement, vaginal atrophy, and deepening of the voice. The expected onset of these changes varies from 1 to 6 months with maximum effect by 2 to 5 years. Contraindications to testosterone therapy include pregnancy, unstable coronary artery disease, and polycythemia."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_t43"
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s6_2",
"title":{
"__html":"Monitoring Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"867931",
"children":[
"Monitoring Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"a2d448",
"children":[
"Patients should be evaluated every 2 to 3 months in the first year, then every 6 to 12 months thereafter to monitor for appropriate response to therapy and adverse reactions. Evaluation includes physical examination and laboratory assessment (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t43",
"wrapId":"3",
"children":[
"Table 43"
]
}
]
},
")"
]
},
". Screening and preventative medicine should be based on the person's anatomy and risk factors."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_t43"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s6_3",
"title":{
"__html":"Gender Confirmation Surgery"
},
"titleNode":{
"type":"section-title",
"hlId":"1ed02a",
"children":[
"Gender Confirmation Surgery"
]
},
"children":[
{
"type":"p",
"hlId":"bda61e",
"children":[
"Gender confirmation surgery is often the last intervention in transgender persons. Many transgender persons do not pursue surgery; for others, however, surgery is essential to alleviate gender dysphoria. Current practice guidelines recommend that clinicians approve gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment unless hormone therapy is not desired or medically contraindicated. For female transgender patients, surgical procedures include augmentation mammoplasty, genital surgery (penectomy, orchiectomy, vaginoplasty, clitoroplasty, vulvoplasty), and nongenital, nonbreast surgery (facial feminization, voice surgery, thyroid cartilage reduction). For male transgender patients, surgical procedures include mastectomy, hysterectomy with oophorectomy, phalloplasty, vaginectomy, scrotoplasty, and implantation of penile and/or testicular prostheses."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"37fdff",
"children":[
"Screening and preventive medicine in transgender patients should be based on the individual's anatomy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s6_4",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"American Psychological Association. Guidelines for psychological practice with transgender and gender nonconforming people. Am Psychol. 2015;70:832-64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26653312",
"target":"_blank"
},
"children":[
"PMID: 26653312"
]
},
" doi:10.1037/a0039906"
]
},
{
"type":"reference",
"children":[
"Coleman EA, Coon SK, Lockhart K, et al. Effect of certification in oncology nursing on nursing-sensitive outcomes. Clin J Oncol Nurs. 2009;13:165-72. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19349263",
"target":"_blank"
},
"children":[
"PMID: 19349263"
]
},
" doi:10.1188/09.CJON.165-172"
]
},
{
"type":"reference",
"children":[
"Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M17-2785",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2018;169:205-213. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29987313",
"target":"_blank"
},
"children":[
"PMID: 29987313"
]
}
]
},
{
"type":"reference",
"children":[
"Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline. Endocr Pract. 2017;23:1437. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29320642",
"target":"_blank"
},
"children":[
"PMID: 29320642"
]
},
" doi:10.4158/1934-2403-23.12.1437"
]
},
{
"type":"reference",
"children":[
"Safer JD, Tangpricha V. Care of the transgender patient. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201907020",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;171:ITC1-ITC16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31261405",
"target":"_blank"
},
"children":[
"PMID: 31261405"
]
}
]
},
{
"type":"reference",
"children":[
"Wylie K, Knudson G, Khan SI, et al. Serving transgender people: clinical care considerations and service delivery models in transgender health. Lancet. 2016;388:401-411. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27323926",
"target":"_blank"
},
"children":[
"PMID: 27323926"
]
},
" doi:10.1016/S0140-6736(16)00682-6"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t43":{
"id":"mk19_b_en_t43",
"number":43,
"bookId":"en",
"title":{
"__html":"Monitoring of Gender-Affirming Hormonal Therapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2880c5",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 43. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t43"
}
]
},
"Monitoring of Gender-Affirming Hormonal Therapy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"423e55",
"class":"col hd l",
"children":[
"Monitoring"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1e4ae",
"class":"col hd l",
"children":[
"Male Transgender Patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2556ef",
"class":"col hd l",
"children":[
"Female Transgender Patients"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c00a2a",
"class":"cell txt l",
"children":[
"Frequency of follow-up",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3fc04",
"class":"cell txt li",
"children":[
"Every 2-3 months during first year of treatment"
]
},
" ",
{
"type":"p",
"hlId":"c6d691",
"class":"cell txt li",
"children":[
"Every 6-12 months thereafter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3fc04",
"class":"cell txt li",
"children":[
"Every 2-3 months during first year of treatment"
]
},
" ",
{
"type":"p",
"hlId":"c6d691",
"class":"cell txt li",
"children":[
"Every 6-12 months thereafter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43c757",
"class":"cell txt l",
"children":[
"Clinical evaluation at each visit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"771875",
"class":"cell txt li",
"children":[
"Blood pressure, weight, pulse"
]
},
" ",
{
"type":"p",
"hlId":"7973f0",
"class":"cell txt li",
"children":[
"Physical examination, including cardiopulmonary and skin examination"
]
},
" ",
{
"type":"p",
"hlId":"bb7c5c",
"class":"cell txt li",
"children":[
"Monitor for appropriate signs of virilization"
]
},
" ",
{
"type":"p",
"hlId":"ffd6a4",
"class":"cell txt li",
"children":[
"Monitor for adverse reactions, excess weight gain, acne, uterine breakthrough bleeding, and cardiovascular impairment, and for psychiatric symptoms in high-risk patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"771875",
"class":"cell txt li",
"children":[
"Blood pressure, weight, pulse"
]
},
" ",
{
"type":"p",
"hlId":"49f98f",
"class":"cell txt li",
"children":[
"Physical examination, including cardiopulmonary examination"
]
},
" ",
{
"type":"p",
"hlId":"bade76",
"class":"cell txt li",
"children":[
"Monitor for appropriate signs of feminization"
]
},
" ",
{
"type":"p",
"hlId":"068ac4",
"class":"cell txt li",
"children":[
"Monitor for adverse reactions; assess for signs of cardiovascular impairment and venous thromboembolism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed28a",
"class":"cell txt l",
"children":[
"Laboratory evaluation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"782288",
"class":"cell txt li",
"children":[
"Testosterone: Every 2-3 months with titration to physiologic male range (350-700 ng/dL [12.1-24.3 nmol/L]); when at goal, measure every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"ced1f5",
"class":"cell txt li",
"children":[
"Estradiol: Measure every 2-3 months until cessation of menstrual bleeding; goal is <50 pg/mL (183.5 pmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"53b5a1",
"class":"cell txt li",
"children":[
"CBC and liver function before therapy initiation, every 3 months in first year, then every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"b9be7e",
"class":"cell txt li",
"children":[
"Lipids: periodic monitoring"
]
},
" ",
{
"type":"p",
"hlId":"971cda",
"class":"cell txt li",
"children":[
"Fasting blood glucose and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in patients with personal or family history of diabetes mellitus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503f73",
"class":"cell txt li",
"children":[
"Testosterone: Measure every 2-3 months with goal <55 ng/dL (1.9 nmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"f52557",
"class":"cell txt li",
"children":[
"Estradiol: Every 2-3 months with titration to physiologic female range; should not exceed peak physiologic range for young healthy women (ideal level <200 pg/mL [734 pmol/L]); when at goal, measure every 6-12 months"
]
},
" ",
{
"type":"p",
"hlId":"b0153f",
"class":"cell txt li",
"children":[
"Patients on spironolactone: monitor serum electrolytes (notably potassium) every 2-3 months during first year of therapy"
]
},
" ",
{
"type":"p",
"hlId":"602c70",
"class":"cell txt li",
"children":[
"Lipids, liver enzymes, and prolactin: periodic and individualized monitoring"
]
},
" ",
{
"type":"p",
"hlId":"f0c563",
"class":"cell txt li",
"children":[
"Fasting blood glucose and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in patients with a personal or family history of diabetes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db7551",
"class":"cell txt l",
"children":[
"Screening"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de80e5",
"class":"cell txt li",
"children":[
"If cervical tissue is present, screen for cervical cancer as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"7ead21",
"class":"cell txt li",
"children":[
"If breast tissue is present, screen for breast cancer with mammography as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"98d695",
"class":"cell txt li",
"children":[
"Baseline bone mineral density testing if risk factors for osteoporosis are present; if low risk, screen for osteoporosis at age 60 years or younger in patients who stop taking hormone therapy after gonadectomy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a8104",
"class":"cell txt li",
"children":[
"Routine cancer screening (colon, prostate) is recommended as in nontransgender persons"
]
},
" ",
{
"type":"p",
"hlId":"e8ca45",
"class":"cell txt li",
"children":[
"Consider baseline bone mineral density testing if risk factors for osteoporosis are present; if low risk, screen for osteoporosis at age 60 years or younger in patients who stop taking hormone therapy after gonadectomy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Patients with comorbid medical conditions may need to be monitored more frequently."
],
[
"Data from Spack NP. Management of transgenderism. JAMA. 2013;309:478-84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23385274",
"target":"_blank"
},
"children":[
"PMID: 23385274"
]
},
" doi:10.1001/jama.2012.165234"
]
]
}
}
}